Last $0.40 USD
Change Today -0.0249 / -5.86%
Volume 146.8K
CBLI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

cleveland biolabs inc (CBLI) Snapshot

Open
$0.42
Previous Close
$0.42
Day High
$0.42
Day Low
$0.40
52 Week High
09/6/13 - $1.80
52 Week Low
08/7/14 - $0.33
Market Cap
22.8M
Average Volume 10 Days
73.3K
EPS TTM
$-0.21
Shares Outstanding
57.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLEVELAND BIOLABS INC (CBLI)

Related News

No related news articles were found.

cleveland biolabs inc (CBLI) Related Businessweek News

View More BusinessWeek News

cleveland biolabs inc (CBLI) Details

Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with significant medical need. Its lead drug candidates include Entolimod, which is being developed as radiation countermeasure for prevention of death from acute radiation syndrome and as an oncology drug; and CBL0137, which is in two multi-center, single agent, dose escalation Phase I studies in subjects with advanced solid tumors. The company’s clinical stage product candidates comprise CBL0102, which has completed Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and Entolimod, which is in Phase I clinical trials for open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity in advanced cancer patients. Its preclinical stage product candidates include CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin. The company has license agreements and collaborations with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, and Buffalo BioLabs. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

44 Employees
Last Reported Date: 03/17/14
Founded in 2003

cleveland biolabs inc (CBLI) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $407.6K
Co-Founder
Total Annual Compensation: $315.1K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $215.3K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $255.5K
Compensation as of Fiscal Year 2013.

cleveland biolabs inc (CBLI) Key Developments

Cleveland BioLabs, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Cleveland BioLabs, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $562,087 against $1,613,262 a year ago. Loss from operations was $4,012,504 against $6,776,618 a year ago. Net loss attributable to the company was $3,961,161 or $0.08 per share basic and diluted share against $3,042,111 or $0.07 per share basic and diluted share a year ago. For the six months, the company reported revenue of $1,896,341 against $2,980,734 a year ago. Loss from operations was $7,531,566 against $14,224,133 a year ago. Net loss attributable to the company was $5,546,533 or $0.11 per diluted share against $12,806,434 or $0.29 per diluted share a year ago. Cash flows used in operating activities was $7,726,002 against $14,123,795 a year ago. The reduced operating losses were due to a narrowed focus of development activities, lower development costs for entolimod's biodefense indication and other cost saving measures. The decrease in Revenues were primarily the result of the completion of certain contracts with the Department of Defense for entolimod's biodefense indication and changes in other contracts with the Ministry of Industry and Trade of the Russian Federation, or MPT.

Cleveland BioLabs, Inc. to Report Q2, 2014 Results on Aug 07, 2014

Cleveland BioLabs, Inc. announced that they will report Q2, 2014 results at 11:30 AM, GMT Standard Time on Aug 07, 2014

Cleveland BioLabs, Inc., Q2 2014 Earnings Call, Aug 07, 2014

Cleveland BioLabs, Inc., Q2 2014 Earnings Call, Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBLI:US $0.40 USD -0.0249

CBLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBLI.
View Industry Companies
 

Industry Analysis

CBLI

Industry Average

Valuation CBLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLEVELAND BIOLABS INC, please visit www.cbiolabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.